CCCC
C4 Therapeutics Inc
3.00$
+1.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +13.0% | +5.8% | -4.3% | -1.3% | -7.0% | -8.6% | -7.2% | -10.5% | +35.3% | -8.4% | +9.3% | |
| – | +21.2% | +3.1% | -1.3% | -1.0% | -5.7% | -9.8% | -3.4% | -7.9% | +24.8% | -4.9% | +7.1% | |
| – | +107.6% | -29.2% | -18.5% | -18.4% | -7.0% | -7.6% | +52.4% | -24.8% | +26.9% | -17.9% | +28.3% | |
| – | +17.1% | +1.8% | +2.3% | -3.2% | -4.2% | -12.2% | -0.2% | -10.6% | +29.5% | -5.2% | +7.6% | |
| – | +2,259.8% | +15.3% | -91.4% | +786.1% | -70.0% | +158.8% | -73.1% | +203.2% | -63.3% | +20.1% | -53.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.4% | +7.5% | -4.3% | -0.5% | +0.2% | -6.9% | -1.5% | -9.3% | -7.7% | -7.7% | +18.5% | |
| – | +41.3% | +28.6% | -1.5% | -20.1% | +4.4% | -9.6% | +8.9% | -19.1% | -8.1% | -17.5% | +77.1% | |
| – | +2.6% | +2.6% | +2.6% | +2.5% | +2.5% | +2.5% | +2.5% | +2.5% | +2.4% | +2.4% | +2.4% | |
| – | +13.3% | +12.7% | -44.0% | +64.7% | -11.7% | -48.6% | +224.5% | -39.8% | -35.6% | -9.9% | +45.0% | |
| – | +13.9% | +4.9% | -4.3% | -1.8% | -11.0% | -9.7% | -10.8% | -11.3% | +66.2% | -8.7% | +5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.1% | +33.6% | +0.6% | +1.2% | +1.4% | +0.3% | +0.2% | +2.2% | +60.9% | +8.0% | +3.7% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.